MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$3.73
0.06 (1.63%)
▲
5d:
+1.36%
30d:
+3.32%
90d:
-12.03%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 4.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 4.2% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $3.73, which is considered extended relative to its 30-day fair value range of $3.60 to $3.72. From a valuation perspective, the stock is trading at a premium (Forward PE: 30.4) compared to its historical average (26.9). At these levels, the market is pricing in 4.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is in a strong downtrend. The price is approaching resistance at $3.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+74.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is in a strong downtrend. The price is approaching resistance at $3.76. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+74.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.60 -
$3.72
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 74.3% below Wall St target ($6.50)
- NEUTRAL: Market pricing in 4.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$3.60 -
$3.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.56
Resistance Level
$3.76
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.45
Wall Street Target
$6.50
(+74.3%)
Revenue Growth (YoY)
-33.1%
Earnings Growth (YoY)
99.5%
Profit Margin
7.9%
Valuation Premium vs History
+4.2% premium
PE vs Historical
30.5 vs 26.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.2%
(market-implied from PE analysis)
1-Year Target
$3.89
(+4%)
2-Year Target
$4.05
(+9%)
3-Year Target
$4.22
(+13%)
3-Yr Target (if PE normalizes)
(PE: 30→27)
PE COMPRESSION
$3.73
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 18.35 | Current EPS (TTM): $0.20
Bull Case
$2.47
(-34%)
Analyst growth -38.8%, PE expands to 20.2
Base Case
$2.25
(-40%)
Market implied -38.8%, PE stable at 18.4
Bear Case
$2.50
(-33%)
Severe decline -20.0%, PE contracts to 15.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 5:48 AM ET
Data refreshes hourly during market hours. Next update: 6:48 AM
Data refreshes hourly during market hours. Next update: 6:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
